On 27 February, the European AIDS Treatment Group (EATG) presented the position on innovative Paediatric Collaboration between the Medicines Patent Pool (MPP) and ViiV Healthcare. The agreement will facilitate and increase the provision of HIV medicines for children in a whole world.
The European AIDS Treatment Group (EATG) supports the collaboration between Medicines Patent Pool (MPP) and ViiV Healthcare. The license for paediatric formulations of the antiretroviral medicine abacavir provides that:
- Manufacturing of paediatric abacavir can take place anywhere in the world.
- It will be possible to distribute the product by sublicenses in 118 countries (which cover 98,7% of the paediatric population in need of HIV treatments).
EATG hopes that collaboration with ViiV Healthcare will further develop and will set up an example for all pharmaceutical companies to sign up the agreements with the MPP, in order to ensure affordable anti-retroviral drugs; enhance sustainable universal access of new treatments to people living with HIV/AIDS; and ensure continued innovation in research and development.
———
– The European AIDS Treatment Group (EATG) welcomes the innovative Paediatric Collaboration between the Medicines Patent Pool (MPP) and ViiV Healthcare
——–
EPHA related articles:
- Access to Medicines, Trade Deals and a New Direction for GSK
- IP isn’t working – NGOs and MEPs call for new methods of medical innovation
- “Medicine shortages is a global public health problem,” by the Pharmaceutical Group of the European Union
- European Parliament adopts draft proposal on Medicines Pricing directive
- Pharmaceutical Group of the European Union launches its vision for greater use of Pharmacists’ Competences
- What role for the EU in the global fight against the HIV/AIDS pandemic?
